Key result
Alteplase infusion showed higher thrombolytic efficacy than bolus-dose alteplase and lower mortality due to initial PE than both bolus alteplase and streptokinase.
Why the study?
Do different thrombolytic regimens (alteplase infusion, bolus-dose alteplase, streptokinase) vary in efficacy and safety for the treatment of pulmonary embolism?
Meta-Analysis
Do different thrombolytic regimens (alteplase infusion, bolus-dose alteplase, streptokinase) vary in efficacy and safety for the treatment of pulmonary embolism?
Answers are grounded in this paper and cite their sources.
Alteplase infusion may reduce PE-related mortality versus bolus alteplase or streptokinase; leaves open confirmation by direct randomized trials.
Recent guidelines recommend bolus-dose alteplase for treating massive pulmonary embolism (PE). However, the safest and most effective treatment is as yet unknown. In the present study, a meta-analysis of published studies of alteplase infusion, bolus-dose alteplase and streptokinase was performed. The outcome measures were as follows: objective assessment of thrombolysis; all-cause mortality; deaths due to initial PE, major bleeding episodes and recurrent PE; and morbidity. In total, 26 studies were identified; however, only two comparative studies of alteplase infusion versus either bolus-dose alteplase or streptokinase were found. Meta-analysis revealed no significant difference between the three regimens, but was compromised by a paucity of data. Crude analysis of summated data on thrombolytic efficacy from all studies revealed that alteplase infusion was more effective than bolus-dose alteplase (relative risk (RR): 1.95; 95% confidence interval (CI): 1.19-3.2), whereas streptokinase was more effective than alteplase infusion (RR: 1.27; 95% CI: 1.09-1.47). Alteplase infusion had a lower mortality due to the initial PE than both bolus-dose alteplase and streptokinase (RR: 0.16; 95% CI: 0.05-0.59 and RR: 0.13; 95% CI: 0.04-0.46, respectively). In conclusion, this evidence suggests that the three thrombolytic agents may vary in efficacy. However, large-scale randomised controlled trials are needed to confirm these results.
No takes yet. Share an insight, caveat, or question.
Capstick et al. (2005) conducted a meta-analysis in massive pulmonary embolism (PE). Alteplase infusion vs. Bolus-dose alteplase or streptokinase was evaluated on Thrombolytic efficacy (RR 1.95, 95% CI 1.19-3.2). Alteplase infusion showed higher thrombolytic efficacy than bolus-dose alteplase and lower mortality due to initial PE than both bolus alteplase and streptokinase.
Synapse has enriched 10 related papers. Consider them for comparative context: